Compare PRSO & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | DARE |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 13.9M |
| IPO Year | 2000 | 2014 |
| Metric | PRSO | DARE |
|---|---|---|
| Price | $0.46 | $0.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $10.00 |
| AVG Volume (30 Days) | 217.3K | ★ 506.3K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.23 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,573,000.00 | $2,807,885.00 |
| Revenue This Year | $18.48 | $2,115.12 |
| Revenue Next Year | $53.57 | $122.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $0.52 | $0.69 |
| 52 Week High | $2.37 | $3.78 |
| Indicator | PRSO | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 27.23 | 30.84 |
| Support Level | N/A | $0.69 |
| Resistance Level | $0.92 | $2.21 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 0.00 | 25.64 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.